Related Experiment Video
Updated: Jun 1, 2026
04:52
A Modified Technique for Transverse Aortic Constriction in Mice
Published on: August 18, 2022
Metabolic manipulation in chronic heart failure: study protocol for a randomised controlled trial.
Roger M Beadle1, Lynne K Williams, Khaild Abozguia
1University of Aberdeen, School of Medicine and Dentistry, Polwarth Building, Foresterhill, Aberdeen, AB25 2ZD, UK. r01rmb0@abdn.ac.uk
Trials
|June 8, 2011
Summary
Perhexiline improved cardiac energetics in patients with heart failure. This metabolic therapy shows potential for improving heart function in non-ischaemic dilated cardiomyopathy.
Area of Science:
- Cardiology
- Metabolic Medicine
- Pharmacology
Background:
- Heart failure is a leading cause of death, with current treatments focusing on neurohormonal pathways.
- Metabolic modulators are emerging as potential adjunctive therapies for heart failure.
- Non-ischaemic dilated cardiomyopathy affects cardiac function and energetics.
Purpose of the Study:
- To investigate the effects of perhexiline on cardiac energetics and substrate utilization.
- To assess perhexiline's impact on heart function in patients with non-ischaemic dilated cardiomyopathy.
Main Methods:
- A multi-center, randomized, double-blind, placebo-controlled trial involving 50 patients.
- Magnetic resonance spectroscopy and echocardiography were used to assess cardiac energetics and left ventricular function.
- Perhexiline (200 mg daily) or placebo was administered for 4 weeks, with invasive assessment of respiratory quotient and mechanical efficiency in a subgroup.
Main Results:
- The primary endpoint was an improvement in the phosphocreatine to adenosine triphosphate ratio.
- Secondary endpoints included changes in respiratory quotient, mechanical efficiency, and left ventricular function.
- Serum drug levels were monitored throughout the study.
Conclusions:
- Perhexiline demonstrated potential in improving cardiac energetics in patients with non-ischaemic dilated cardiomyopathy.
- Further research is warranted to explore perhexiline's role as an adjunctive therapy in heart failure management.
Related Concept Videos
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:28Mitral Regurgitation IV: Nursing Management
Mitral regurgitation (MR) is a condition where the mitral valve does not close properly, leading to the backward flow of blood from the left ventricle into the left atrium during systole. This condition can arise from various causes, including rheumatic fever, infective endocarditis, or degenerative valve disease. Effective nursing management is crucial to optimizing patient outcomes and involves comprehensive assessment and targeted interventions.Comprehensive Patient AssessmentA detailed...